"You decide and we provide."
Cart 0

Bristol-Myers NASH drug reduces liver fat in midstage study




reutersCOMPANYNEWS companyNews

April 22 (Reuters) - Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday.




Older Post Newer Post


Leave a comment

Please note, comments must be approved before they are published